Ocugen (OCGN) Competitors

Ocugen logo
$0.76 -0.02 (-2.11%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.79 +0.03 (+3.87%)
As of 06:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OCGN vs. MRNA, PFE, JANX, CVAC, and MLTX

Should you buy Ocugen stock or one of its competitors? Ocugen's main competitors and comparable companies include Moderna (MRNA), Pfizer (PFE), Janux Therapeutics (JANX), CureVac (CVAC), and MoonLake Immunotherapeutics (MLTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Ocugen compare to Moderna?

Ocugen (NASDAQ:OCGN) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Ocugen currently has a consensus target price of $9.50, indicating a potential upside of 1,155.45%. Moderna has a consensus target price of $120.25, indicating a potential downside of 41.85%. Given Ocugen's stronger consensus rating and higher probable upside, research analysts plainly believe Ocugen is more favorable than Moderna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocugen
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Moderna
4 Sell rating(s)
15 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.08

Ocugen has a net margin of 0.00% compared to Moderna's net margin of -110.46%. Moderna's return on equity of -25.79% beat Ocugen's return on equity.

Company Net Margins Return on Equity Return on Assets
OcugenN/A -127,987.80% -98.50%
Moderna -110.46%-25.79%-15.85%

10.3% of Ocugen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ocugen has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocugen$4.41M58.22-$67.85M-$0.20N/A
Moderna$1.94B43.04-$2.82B-$7.10N/A

In the previous week, Moderna had 35 more articles in the media than Ocugen. MarketBeat recorded 40 mentions for Moderna and 5 mentions for Ocugen. Ocugen's average media sentiment score of 0.72 beat Moderna's score of 0.40 indicating that Ocugen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocugen
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Moderna
8 Very Positive mention(s)
9 Positive mention(s)
12 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Neutral

Ocugen has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market. Comparatively, Moderna has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Summary

Ocugen beats Moderna on 8 of the 15 factors compared between the two stocks.

How does Ocugen compare to Pfizer?

Pfizer (NYSE:PFE) and Ocugen (NASDAQ:OCGN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

In the previous week, Pfizer had 40 more articles in the media than Ocugen. MarketBeat recorded 45 mentions for Pfizer and 5 mentions for Ocugen. Ocugen's average media sentiment score of 0.72 beat Pfizer's score of 0.37 indicating that Ocugen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pfizer
14 Very Positive mention(s)
7 Positive mention(s)
14 Neutral mention(s)
8 Negative mention(s)
2 Very Negative mention(s)
Neutral
Ocugen
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pfizer has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$62.58B2.59$7.77B$0.7040.58
Ocugen$4.41M58.22-$67.85M-$0.20N/A

Pfizer has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Pfizer presently has a consensus target price of $30.32, indicating a potential upside of 6.73%. Ocugen has a consensus target price of $9.50, indicating a potential upside of 1,155.45%. Given Ocugen's stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than Pfizer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer
2 Sell rating(s)
14 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.18
Ocugen
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Pfizer has a net margin of 6.34% compared to Ocugen's net margin of 0.00%. Pfizer's return on equity of 19.88% beat Ocugen's return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer6.34% 19.88% 8.52%
Ocugen N/A -127,987.80%-98.50%

68.4% of Pfizer shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Pfizer beats Ocugen on 9 of the 15 factors compared between the two stocks.

How does Ocugen compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Janux Therapeutics' return on equity of -11.80% beat Ocugen's return on equity.

Company Net Margins Return on Equity Return on Assets
Janux TherapeuticsN/A -11.80% -10.97%
Ocugen N/A -127,987.80%-98.50%

Janux Therapeutics currently has a consensus target price of $36.92, indicating a potential upside of 244.75%. Ocugen has a consensus target price of $9.50, indicating a potential upside of 1,155.45%. Given Ocugen's higher probable upside, analysts clearly believe Ocugen is more favorable than Janux Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.63
Ocugen
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Janux Therapeutics had 10 more articles in the media than Ocugen. MarketBeat recorded 15 mentions for Janux Therapeutics and 5 mentions for Ocugen. Ocugen's average media sentiment score of 0.72 beat Janux Therapeutics' score of 0.19 indicating that Ocugen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Janux Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Ocugen
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ocugen has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Janux Therapeutics$10M65.52-$113.62M-$1.59N/A
Ocugen$4.41M58.22-$67.85M-$0.20N/A

Janux Therapeutics has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market.

Summary

Janux Therapeutics beats Ocugen on 11 of the 15 factors compared between the two stocks.

How does Ocugen compare to CureVac?

Ocugen (NASDAQ:OCGN) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

CureVac has a net margin of 199.92% compared to Ocugen's net margin of 0.00%. CureVac's return on equity of -23.03% beat Ocugen's return on equity.

Company Net Margins Return on Equity Return on Assets
OcugenN/A -127,987.80% -98.50%
CureVac 199.92%-23.03%-19.09%

Ocugen presently has a consensus price target of $9.50, suggesting a potential upside of 1,155.45%. Given Ocugen's stronger consensus rating and higher possible upside, equities analysts clearly believe Ocugen is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocugen
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
CureVac
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Ocugen had 5 more articles in the media than CureVac. MarketBeat recorded 5 mentions for Ocugen and 0 mentions for CureVac. Ocugen's average media sentiment score of 0.72 beat CureVac's score of 0.00 indicating that Ocugen is being referred to more favorably in the media.

Company Overall Sentiment
Ocugen Positive
CureVac Neutral

Ocugen has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market.

10.3% of Ocugen shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CureVac has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocugen$4.41M58.22-$67.85M-$0.20N/A
CureVac$70.74M14.78$175.50M$0.726.47

Summary

Ocugen beats CureVac on 8 of the 15 factors compared between the two stocks.

How does Ocugen compare to MoonLake Immunotherapeutics?

Ocugen (NASDAQ:OCGN) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Ocugen has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Ocugen currently has a consensus price target of $9.50, indicating a potential upside of 1,155.45%. MoonLake Immunotherapeutics has a consensus price target of $31.33, indicating a potential upside of 178.52%. Given Ocugen's higher possible upside, analysts plainly believe Ocugen is more favorable than MoonLake Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocugen
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
MoonLake Immunotherapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.60

Ocugen has higher revenue and earnings than MoonLake Immunotherapeutics. Ocugen is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocugen$4.41M58.22-$67.85M-$0.20N/A
MoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.67N/A

MoonLake Immunotherapeutics' return on equity of -79.95% beat Ocugen's return on equity.

Company Net Margins Return on Equity Return on Assets
OcugenN/A -127,987.80% -98.50%
MoonLake Immunotherapeutics N/A -79.95%-56.40%

10.3% of Ocugen shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, MoonLake Immunotherapeutics had 7 more articles in the media than Ocugen. MarketBeat recorded 12 mentions for MoonLake Immunotherapeutics and 5 mentions for Ocugen. Ocugen's average media sentiment score of 0.72 beat MoonLake Immunotherapeutics' score of -0.09 indicating that Ocugen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocugen
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MoonLake Immunotherapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Ocugen and MoonLake Immunotherapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Ocugen News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCGN vs. The Competition

MetricOcugenBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$262.28M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.6634.2628.24
Price / Sales58.2215.788.485.70
Price / CashN/A22.9521.0121.90
Price / Book-15.134.184.463.72
Net Income-$67.85M-$24.15M$3.52B$393.10M
7 Day Performance-21.21%-7.78%-5.92%-5.76%
1 Month Performance-3.02%-5.96%-4.58%-7.14%
1 Year Performance-34.20%-8.08%-1.93%-7.46%

Ocugen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCGN
Ocugen
1.6122 of 5 stars
$0.76
-2.1%
$9.50
+1,155.5%
-34.8%$262.28M$4.41MN/A116
MRNA
Moderna
1.3949 of 5 stars
$269.00
+5.8%
$113.75
-57.7%
+735.2%$103.15B$1.94BN/A4,700
PFE
Pfizer
2.8188 of 5 stars
$29.27
-0.4%
$30.39
+3.8%
+13.4%$175.50B$62.58B10.1075,000
JANX
Janux Therapeutics
2.7098 of 5 stars
$12.76
-27.6%
$36.92
+189.4%
-62.7%$1.11B$10MN/A113
CVAC
CureVac
N/A$4.66
flat
N/AN/A$1.05B$70.74M6.47880

Related Companies and Tools


This page (NASDAQ:OCGN) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners